CCL2 and cancer: In addition to the clinical significance of KRAS and other driver mutations of lung and other cancers in MPE that needs to be established, open questions that remain include whether the hypoxic pleural environment impacts MPE development and whether it triggers phenotypic changes in pleural metastasized tumour cells, including the KRAS/CCL2 axis reported here.